Whalesbook
Shipping Assumptions Under Strain
The assumption that goods move freely is faltering. Disruptions in West Asia are adding 10-15 days to transit times and sharp increases in freight and insurance costs. These higher costs cannot easily be passed to customers due to current margin pressures, hurting exporter competitiveness.
Pharma Sector's Input Reliance
Modest logistics cost increases can shift competitiveness for businesses on tight margins. This pressure is particularly acute in pharmaceuticals and preventive healthcare. India exported over $30 billion in medicines last year, but relies heavily on imported critical inputs, especially APIs from China. This creates a clear dependency.
Concentrated Routes Pose Risk
Late input arrivals delay production, and disrupted outbound routes prevent finished product movement as planned. Logistics delays quickly impact manufacturing timelines and, in regulated markets, compliance. India's export system, efficient in stable times, lacks adaptability to disruptions. A large portion of exports uses limited routes, leaving little room for adjustment.
Contracts and Finances Under Pressure
Smaller exporters often lack the financial cushion to absorb sudden cost increases, impacting their bottom lines. Alternative route decisions are often made under pressure, when costs and timelines are already unfavorable. Contracts need to evolve to include mechanisms for price and delivery adjustments during disruptions. Access to working capital for exporters often lags behind the immediate needs created by these events. Trade agreements must also adapt to support faster clearances and better coordination.
Resilience Now Key to Competitiveness
In an era of routine disruptions, competitiveness hinges on maintaining shipments even when conditions worsen. Resilience in pharmaceuticals relies on sourcing flexibility. Domestic API capacity grows slowly, making alternate sourcing arrangements critical.